Navigation Links
Bowel Cancer Screening Program

Managing current demand for bowel cancer services has become an increasingly important issue with the roll out of Australia’s National Bowel Cancer Screening Program.//

Four separate articles in the latest Medical Journal of Australia (MJA) look at various issues related to the implementation of the program.

In his editorial for the MJA, Professor Finlay Macrae, Head of Colorectal Medicine and Genetics at Royal Melbourne Hospital, says there are some uncertainties about whether the health system can cope with the extra need for colonoscopies that will be generated by the program.

“It should be possible to spread the load across both private and public facilities, with appropriate jurisdictional contractual agreements between Federal and State Governments, and optimal use of existing facilities and personnel,” says Prof Macrae.

Prof Macrae says it is the responsibility of hospital administrators to identify any funding opportunities for extra services and match resources to the increased demand for services.

A study by Dr Jane Young, Executive Director of the Surgical Outcomes Research Centre at the University of Sydney, and colleagues, on behalf of the Cancer Council NSW shows hospital administrators can also aid uptake of the current guidelines for colorectal cancer treatment and care.

“Our findings show that, on average, 78 per cent of relevant guidelines were followed for individual patients,” says Dr Young.

“Hospital caseload influenced the use of some guidelines, highlighting the importance of institutional factors.

“The considerable variation found in the application of the National Health and Medical Research Council’s guidelines for colorectal cancer implies that better strategies are needed to ensure greater compliance.”

In a separate study published in the MJA, Dr Charlie Viiala, a gastroenterologist from Fremantle Hospital, and colleagues, f ound that waiting times for patients having semi-urgent and routine colonoscopies in public hospitals were longer than clinically desirable, but waiting times for urgent colonoscopies were well within the recommended timeframe.

Dr Viiala suggests reduced waiting times could be achieved by increasing the capacity and productivity of endoscopic units or by ensuring the appropriateness of procedures, for example by stricter adherence to guidelines for surveillance colonoscopies.

“The recognition of risk factors for a diagnosis of cancer, including age over 65 years and certain blood-loss indications, could ensure that most patients with cancer are diagnosed within a three month waiting period,” says Dr Viiala.

Associate Professor Cameron Platell of the School of Surgery and Pathology at the University of Western Australia, and colleagues, conducted a study into survival rates of colorectal cancer patients in public versus private hospitals.

They found patients receiving treatment in a private hospital had improved survival outcomes compared with those treated in public hospitals.

“If these observed improvements are a result of superior treatment, and not just patient selection, then they raise serious concerns regarding equity and access to treatment,” says Assoc Prof Platell.

“The reasons for these improved survival outcomes in private hospitals need to be further elucidated.”

Souce-AMA
SRM
'"/>




Related medicine news :

1. Bowel diseases linked to bug in milk
2. Hope For Patients With Inflammatory Bowel Disease
3. Cannabinoids - Antidepressant And Inflammatory Bowel Disease Treatment
4. Eating Red and Processed Meat may cause Bowel cancer
5. Just Had Bowel Surgery? Chew Gum For A Speedy Recovery
6. Delay In Life-Saving Bowel Cancer Screening Programme In UK
7. National Bowel Cancer Screening Programme Lauded
8. Bowel Cancer Drug Campaigner Dies After Surgery
9. New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders
10. Parasitic Worms Could Be Used To Treat Bowel Disease
11. Inflammatory Bowel Diseases Cured By Parasitic Worms
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... Ron ... an option to senior, upper-level executives speaking at a business luncheon today, "It ... high-level executive is an asset to be fully realized and activated by the ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a ... Reward” is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible ... we returned to our cars, my sister-in-law invited us to come over before the ...
(Date:9/25/2017)... September 25, 2017 - Orlando, FL, Microsoft Ignite Conference (PRWEB) , ... ... ... Hosts, Inc . announced today that they have teamed up to deliver Netmail’s Hadron ... on-demand service from a HIPAA/HITRUST compliant Azure Cloud. Netmail will be demo-ing their Hadron ...
(Date:9/25/2017)... ... ... Ash Borers kill Ash trees in as little as 1-3 years. The signs ... by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in ... signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
(Date:9/24/2017)... & Caicos Islands, BWI (PRWEB) , ... September 25, 2017 , ... ... to announce the resort is re-opening on October 1st. And, throughout the month ... three bedroom oceanfront rentals. , Hurricane Irma and Maria have passed and damage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: